One Degree Advisors Inc Makes New $206,000 Investment in Johnson & Johnson (NYSE:JNJ)

One Degree Advisors Inc bought a new stake in Johnson & Johnson (NYSE:JNJ) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,244 shares of the company’s stock, valued at approximately $206,000.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Elios Financial Group Inc. raised its stake in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC raised its position in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after buying an additional 67 shares in the last quarter. MBA Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc increased its stake in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after acquiring an additional 69 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on JNJ. Guggenheim restated a “neutral” rating and issued a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Wall Street Zen lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 18th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $174.50.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $170.72 on Thursday. The company has a market capitalization of $411.14 billion, a PE ratio of 18.26, a PEG ratio of 2.17 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company’s 50 day moving average price is $158.53 and its 200 day moving average price is $157.10. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $172.18.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson’s revenue was up 5.8% on a year-over-year basis. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.